# Innostellar Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innostellar-biotherapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.innostellarbio.cn
- Latest round: Series B (Jun 11, 2024)
- Investors on record: 2

## About

Based in Shanghai, China, and founded in 2020, Innostellar Biotherapeutics is a biotechnology developer, dedicated to the development and manufacture of innovative drugs for gene therapy. The company has set up a branch office in Suzhou. The founder as well as the CEO, Fenghua Wang, is a director of Shanghai Ophthalmic Engineering and Technology Research Centre. It has received 3 INDs (Investigational New Drug). In June 2024, Innostellar Biotherapeutics closed series B+ funding led by new investor Shanghai Healthcare Capital.

Innostellar Biotherapeutics has built a platform process for manufacturing AAV products in compliance with GMP regulations. The company has developed three manufacturing pipelines, LX101 for the treatment of RPE65 mutation-associated inherited retinal dystrophy (IRD), LX102 for the treatment of wet age-related macular degeneration, and LX103 for the treatment of X-linked retinal schwannoma.

The company generates revenue by developing and delivering innovative medicines for the treatment of hereditary and chronic diseases of the eye.

The company will accelerate the R&D and industrialisation process in the field of innovative gene therapy drugs.

## Funding rounds

- Series B, Jun 11, 2024 — Shanghai Alliance Investment, Shanghai Healthcare Capital

## Investors

- Shanghai Alliance Investment — Series B
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series B